Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca's chief executive, Pascal Soriot.
So the idea that he would stake his company's future on a takeover of another pharma giant left investors scratching their heads, with many running for cover in recent days.
Yet the concern over reported talks might be creating an opportunity. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb, shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. Either way, AstraZeneca shares are still down over 10% for the year. They trade at less than 15 times forward earnings, well below their 18-times average over the past decade.
Soriot built his reputation by doing almost the exact opposite of what he might now be contemplating. After rebuffing Pfizer's $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry's top growth stories.
He did so by focusing on internal research and development paired with smaller deals, rather than relying on unwieldy corporate consolidation. The largest was the acquisition of the rare-disease company Alexion for $39 billion. Over the past decade, revenue rose to nearly $60 billion from about $25 billion, turning the company into one of the U.K.'s most valuable corporations.
But could Soriot be harboring larger global ambitions? At roughly $250 billion, AstraZeneca's market capitalization is still dwarfed by such rivals as Eli Lilly and Johnson & Johnson, sitting around $1 trillion and $600 billion, respectively. That gap helps explain why he might have considered a megamerger on a scale the industry hasn't seen in years, one that could create a $400 billion global pharma company.
Investors were unimpressed by the reported talks. Megamergers built on cost synergies and raw corporate scale have largely fallen out of favor on Wall Street. Big drugmakers increasingly prefer bolting on promising biotech. Even the largest transactions of the past decade, such as Pfizer's $43 billion purchase of Seagen in 2023 or Bristol-Myers Squibb's $74 billion acquisition of Celgene in 2019, involved swallowing a large biotech, not a classic merger of two pharma giants for cost efficiencies.
The knock on such megamergers is well-known: They distract management, sow years of organizational chaos, and invite regulatory scrutiny. The antitrust risk would be acute in a takeover of Bristol-Myers Squibb given the substantial overlapping portfolios both companies maintain in oncology. These deals also don't reliably deliver more innovation over the long term.
Political timing might be playing a role. A more permissive regulatory climate under the Trump administration has opened a rare window of opportunity for big deals, said Jared Holz, a healthcare strategist at Mizuho. AstraZeneca has made no secret of its push to become a more U.S.-centric company, stepping up investment in America and recently completing a direct listing on the New York Stock Exchange.
AstraZeneca was already facing pressure before reports of a possible transaction surfaced. Shares tumbled early last month after the company revealed that a closely watched heart medication failed in a late-stage clinical trial. The setback raised uncomfortable questions about whether the company can hit its ambitious goal of $80 billion in annual sales by 2030. More broadly, investors are starting to ask questions about the company's long-term growth drivers when major oncology blockbusters such as Tagrisso, Imfinzi and Calquence lose patent protection in the 2030s.
Then there was the reported target. Bristol-Myers Squibb is staring down immediate patent expirations on such core revenue drivers as the cancer blockbuster Opdivo and the blood thinner Eliquis. Wall Street naturally wants to know why one of big pharma's top growth stories would tie itself to a company that might soon be shrinking. The deal report raised an awkward question: Does AstraZeneca have less faith in its own organic pipeline than it has been telling the market?
Investor concern might be overblown. In all likelihood, the acquisition talks will go nowhere, and AstraZeneca will return to the strategy that built it: growing its own deep cancer pipeline and continuing to make more-manageable deals to push into such areas as heart and metabolic medicine. That is the reliable playbook.
Even if Soriot pushes this or another large transaction over the finish line, it need not be a disaster. Despite their bad rap, many megamergers have fared reasonably well. AbbVie's acquisition of Allergan worked out fine, with Botox and other aesthetics products helping cushion Humira's decline. Roche's purchase of Genentech was a triumph, securing control of such cancer blockbusters as Avastin and Herceptin.
Soriot built his name by resisting a megadeal once before. Reversing that stance would be a big risk. But he has earned some leeway from investors.
Comments